Strategy Development

• Corporate R&D strategy
    • Where to go and where not to go
    • Maximization of therapeutic and portfolio synergy
    • Close monitoring of the R&D environment
• Portfolio strategy

    • By therapeutic area and disease
    • By mechanism of action
    • By category and technological synergy
• Asset strategy

   • Clinical development: true unmet needs, entry and subsequent indications, biomarker strategy, 
     Clinical Development Plan(CDP), Target Product Profile(TPP)
   • Global or MRCT(multiregional clinical trials) planning

Scientific and Medical Support 
in execution of your CDP

• Data gap analysis for first-in-human studies
• IND preparedness
• Medical support in interacting with the US FDA, MFDS (Korea), and other health authorities
• Scientific and medical oversight of on-going trials & clinical data interpretation
• Development and execution of Advisory Boards (domestic & international)
• Study steering committee membership
• Project planning and management
• Liaison with KOLs and collaborative groups
• Training of therapeutic area and protocol

Specialty in Hematology-oncology services

• Disease areas: lung cancer, breast cancer, gastric cancer, hepatocellular carcinoma, head & neck cancer,      leukemia/lymphoma, uterine cancer, renal cell cancer, and other haematologic diseases & solid tumors
• Therapeutic classes: small molecules, biologicals (antibodies, ADC, BiTE, etc), immune oncology, cell              therapies, gene therapies, oncolytic viruses, microbiomes, cancer vaccines, radiopharmaceuticals